The company was accused of overcharging the government for EpiPens.
Last week, around 81,000 EpiPen devices were recalled in foreign countries.
A small win in a losing war against soaring drug prices.
It was an ordinary morning, I had just opened my computer when a new email flitting by on the top right of my screen caught
They get a discount, but the Pentagon paid retail prices for the EpiPen for years.
The pharmaceutical industry has had a rough go of it lately. Between negative headlines (with the recent Mylan EpiPen controversy only the latest controversy), congressional inquiries and calls from insurers and the medical community to defend the price of medications, today's value-focused healthcare landscape presents an unprecedented set of challenges for the sector.
Drug companies, who are spending $90 million to stop Proposition 61, will continue to overcharge Californians until we pass Prop 61 to stop their price gouging.
As part of the settlement, Mylan won't have to acknowledge any wrongdoing.
The current discussion around the EpiPen appropriately focuses on the acute need to help patients with access to EAIs. However, we believe the U.S. needs to urgently address the market forces that have led to this problem.
EpiPen has become the industry standard and in most cases the only option, and a price surge for this product certainly warrants this current uproar.
The soaring cost of EpiPens is the latest in a long run of wildly increased costs of prescription drugs that are unaffordable to many, such as Turing's Daraprim for toxoplasmosis (5,000 percent overnight price increase) and Gilead's Sovaldi for hepatitis C ($84,000 for a 12-week treatment).